seltorexant

orexin-2 receptor antagonist

Also Known As:

((3aR,6aS)-5-(4,6-Dimethyl-2-pyrimidinyl)hexahydropyrrolo(3,4-c)pyrrol-2(1H)-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)methanone; JNJ-42847922; MIN-202; Methanone, ((3aR,6aS)-5-(4,6-dimethyl-2-pyrimidinyl)hexahydropyrrolo(3,4-c)pyrrol-2(1H)-yl)(2-fluoro-6-(2H-1,2,3-triazol-2-yl)phenyl)-

Networked: 11 relevant articles (1 outcomes, 7 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Heterocyclic Compounds: 198
- 1-Ring Heterocyclic Compounds
  - Azoles: 2138
    - Triazoles: 1533
      - seltorexant: 11
    - Pyrroles: 369
      - seltorexant: 11
  - Pyrimidines: 510
    - seltorexant: 11

Experts

1.	Luthringer, Remy: 4 articles (10/2019 - 01/2018)
2.	de Boer, Peter: 4 articles (10/2019 - 12/2018)
3.	van der Ark, Peter: 4 articles (10/2019 - 01/2018)
4.	Drevets, Wayne: 3 articles (10/2019 - 01/2019)
5.	Zuiker, Rob: 3 articles (10/2019 - 01/2019)
6.	van Gerven, Joop: 3 articles (10/2019 - 01/2018)
7.	van Nueten, Luc: 3 articles (10/2019 - 12/2018)
8.	Drevets, Wayne C: 2 articles (12/2021 - 01/2018)
9.	Jacobs, Gabriel: 2 articles (10/2019 - 01/2019)
10.	Kent, Justine: 2 articles (10/2019 - 01/2019)

Related Diseases

1.	Sleep Initiation and Maintenance Disorders (Insomnia) 12/01/2022 - "Findings of this study suggest that seltorexant 20 mg is more effective than placebo, especially in individuals with moderate or insomnia symptoms at baseline. " 01/01/2018 - "A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity." 01/01/2018 - "The primary objective was to investigate the effect of seltorexant on sleep efficiency after single and multiple dose administration in subjects with insomnia disorder without psychiatric comorbidity. " 09/01/2015 - "Characterization of JNJ-42847922, a Selective Orexin-2 Receptor Antagonist, as a Clinical Candidate for the Treatment of Insomnia." 01/01/2018 - "Seltorexant is a potent and selective antagonist of the orexin-2 receptor that is being developed for the treatment of insomnia and major depressive disorder. "
2.	Major Depressive Disorder (Major Depressive Disorders) 12/08/2021 - "Efficacy and Safety of Seltorexant as Adjunctive Therapy in Major Depressive Disorder: A Phase 2b, Randomized, Placebo-Controlled, Adaptive Dose-Finding Study." 01/01/2018 - "Seltorexant is a potent and selective antagonist of the orexin-2 receptor that is being developed for the treatment of insomnia and major depressive disorder. " 12/01/2022 - "Selective Orexin Receptor Antagonists as Novel Augmentation Treatments for Major Depressive Disorder: Evidence for Safety and Efficacy From a Phase 2B Study of Seltorexant." 12/08/2021 - "Seltorexant, a selective antagonist of human orexin-2 receptors, demonstrated antidepressant effects in a previous exploratory study in patients with major depressive disorder (MDD). " 10/02/2019 - "Correction to: The selective orexin-2 antagonist seltorexant (JNJ-42847922/MIN-202) shows antidepressant and sleep-promoting effects in patients with major depressive disorder."
3.	Sleepiness 12/01/2018 - "At doses ⩾20 mg, JNJ-42847922 consistently induced somnolence on all study days. " 12/01/2018 - "Observed- and self-reported somnolence was used to evaluate the principal pharmacodynamic effect of JNJ-42847922. " 12/01/2018 - "Multiple daytime administration of the selective orexin-2 receptor antagonist JNJ-42847922 induces somnolence in healthy subjects without residual central effects." 12/08/2021 - "The most common (≥5%) adverse events with seltorexant were somnolence, headache, and nausea. " 09/01/2015 - "In a single ascending dose study conducted in healthy subjects, JNJ-42847922 increased somnolence and displayed a favorable pharmacokinetic and safety profile for a sedative/hypnotic, thus emerging as a promising candidate for further clinical development for the treatment of insomnia. "
4.	Drug-Related Side Effects and Adverse Reactions 01/01/2019 - "Treatment with seltorexant was associated with mild, self-limiting adverse drug reactions. "
5.	Nausea 12/08/2021 - "The most common (≥5%) adverse events with seltorexant were somnolence, headache, and nausea. "

Related Drugs and Biologics

1.	Antidepressive Agents (Antidepressants)
2.	Orexin Receptor Antagonists
3.	Orexin Receptors
4.	Hypnotics and Sedatives (Sedatives)
5.	Orexins
6.	suvorexant
7.	daridorexant
8.	lemborexant

Related Therapies and Procedures

1.	Therapeutics